Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 11/2018

01-11-2018 | Psychosocial Aspects (SS Jaser, Section Editor)

Biopsychosocial Factors Associated With Satisfaction and Sustained Use of Artificial Pancreas Technology and Its Components: a Call to the Technology Field

Authors: Gregory P. Forlenza, Laurel H. Messer, Cari Berget, R. Paul Wadwa, Kimberly A. Driscoll

Published in: Current Diabetes Reports | Issue 11/2018

Login to get access

Abstract

Purpose of Review

Summarize biopsychosocial factors associated with using continuous glucose monitors (CGMs), insulin pumps, and artificial pancreas (AP) systems and provide a “call to the field” about their importance to technology uptake and maintained use.

Recent Findings

Insulin pumps and CGMs are becoming standard of care for individuals with type 1 diabetes (T1D). AP systems combining a CGM, insulin pump, and automated dosing algorithm are available for commercial use. Despite improved glycemic control with AP system use, numerous barriers exist which may limit their benefit. Studies on components of AP systems (pumps, CGMs) are limited and demonstrate mixed results of their impact on fear of hypoglycemia, adherence, quality of life, depression and anxiety, and diabetes distress. Studies examining biopsychological factors associated specifically with sustained use of AP systems are also sparse.

Summary

Biological, psychological and social impacts of AP systems have been understudied and the information they provide has not been capitalized upon.
Literature
1.
DeSalvo DJ, Miller KM, Hermann JM, Maahs DM, Hofer SE, Clements MA, et al. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: international comparison from the T1D exchange and DPV initiative. Pediatr Diabetes 2018.
2.
Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38(6):971–8.PubMed
3.
Sherr JL, Hermann JM, Campbell F, Foster NC, Hofer SE, Allgrove J, et al. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia. 2016;59(1):87–91.PubMed
4.
Facchinetti A. Continuous glucose monitoring sensors: past, present and future algorithmic challenges. Sensors (Basel). 2016;16(12):2093–104.
5.
Petrie JR, Peters AL, Bergenstal RM, Holl RW, Fleming GA, Heinemann L. Improving the clinical value and utility of CGM systems: issues and recommendations : a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetologia. 2017;60(12):2319–28.PubMed
6.
Wadwa RP, Laffel LM, Shah VN, Garg SK. Accuracy of a factory-calibrated, real-time continuous glucose monitoring system during 10 days of use in youth and adults with diabetes. Diabetes Technol Ther. 2018;20(6):395–402.PubMed
7.
Shah VN, Laffel LM, Wadwa RP, Garg SK. Performance of a factory-calibrated real-time continuous glucose monitoring system utilizing an automated sensor applicator. Diabetes Technol Ther. 2018;20(6):428–33.PubMed
8.
Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017;19(3):155–63.PubMedPubMedCentral
9.
Messer LH, Forlenza GP, Wadwa RP, Weinzimer SA, Sherr JL, Hood KK, et al. The dawn of automated insulin delivery: a new clinical framework to conceptualize insulin administration. Pediatr Diabetes. 2018;19(1):14–7.PubMed
10.
Forlenza GP, Shulman DI, Wood MA, Bailey TS, Bode BW, Buckingham B, et al. Overnight to early-morning glycemic outcomes in children using the MiniMed™ 670G hybrid closed-loop (HCL) system. Diabetes. 2018;67(S1):W204.
11.
Polonsky WH, Hessler D. What are the quality of life-related benefits and losses associated with real-time continuous glucose monitoring? A survey of current users. Diabetes Technol Ther. 2013;15(4):295–301.PubMed
12.
Messer LH, Berget C, Beatson C, Polsky S, Forlenza GP. Preserving skin integrity with chronic device use in diabetes. Diabetes Technol Ther. 2018;20(S2):S254–s64.PubMed
13.
Wadwa RP, Fiallo-Scharer R, Vanderwel B, Messer LH, Cobry E, Chase HP. Continuous glucose monitoring in youth with type 1 diabetes. Diabetes Technol Ther. 2009;11(Suppl 1):S83–91.PubMed
14.
Giani E, Snelgrove R, Volkening LK, Laffel LM. Continuous glucose monitoring (CGM) adherence in youth with type 1 diabetes: associations with biomedical and psychosocial variables. J Diabetes Sci Technol. 2017;11(3):476–83.PubMed
15.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study G, Beck RW, Buckingham B, Miller K, Wolpert H, Xing D, et al. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2009;32(11):1947–53.
16.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study G. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care. 2010;33(1):17–22.
17.
Forlenza GP, Buckingham B, Maahs DM. Progress in diabetes technology: developments in insulin pumps, continuous glucose monitors, and progress towards the artificial pancreas. J Pediatr. 2016;169:13–20.PubMed
18.
Rodbard D. Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol Ther. 2016;18(Suppl 2):S3–S13.PubMed
19.
Tanenbaum ML, Hanes SJ, Miller KM, Naranjo D, Bensen R, Hood KK. Diabetes device use in adults with type 1 diabetes: barriers to uptake and potential intervention targets. Diabetes Care. 2017;40(2):181–7.PubMed
20.
Battelino T, Conget I, Olsen B, Schutz-Fuhrmann I, Hommel E, Hoogma R, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012;55(12):3155–62.PubMedPubMedCentral
21.
Ruedy KJ, Parkin CG, Riddlesworth TD, Graham C, Group DS. Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: results from the DIAMOND trial. J Diabetes Sci Technol. 2017;11(6):1138–46.PubMedPubMedCentral
22.
•• Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317(4):371–8 A large randomized clinical trial showing the clinical benefit of reduction in glycemic control in individuals with T1D using continuous glucose monitors compared to those who do not. PubMed
23.
Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167(6):365–74.PubMed
24.
Riddlesworth T, Price D, Cohen N, Beck RW. Hypoglycemic event frequency and the effect of continuous glucose monitoring in adults with type 1 diabetes using multiple daily insulin injections. Diabetes Ther. 2017;8(4):947–51.PubMedPubMedCentral
25.
Bergenstal RM, Rosenstock J, Bastyr EJ 3rd, Prince MJ, Qu Y, Jacober SJ. Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine. Diabetes Care. 2014;37(3):659–65.PubMed
26.
Secher AL, Stage E, Ringholm L, Barfred C, Damm P, Mathiesen ER. Real-time continuous glucose monitoring as a tool to prevent severe hypoglycaemia in selected pregnant women with type 1 diabetes—an observational study. Diabet Med. 2014;31(3):352–6.PubMed
27.
Hermanides J, Devries JH. Sensor-augmented insulin pump more effective than multiple daily insulin injections for reducing HbA1C in people with poorly controlled type 1 diabetes. Evid Based Med. 2011;16(2):46–8.PubMed
28.
Beck RW, Riddlesworth TD, Ruedy KJ, Kollman C, Ahmann AJ, Bergenstal RM, et al. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(9):700–8.PubMed
29.
Ives B, Sikes K, Urban A, Stephenson K, Tamborlane WV. Practical aspects of real-time continuous glucose monitors: the experience of the Yale Children’s Diabetes Program. Diabetes Educ. 2010;36(1):53–62.PubMed
30.
Messer L, Ruedy K, Xing D, Coffey J, Englert K, Caswell K, et al. Educating families on real time continuous glucose monitoring: the DirecNet navigator pilot study experience. Diabetes Educ. 2009;35(1):124–35.PubMedPubMedCentral
31.
Englert K, Ruedy K, Coffey J, Caswell K, Steffen A, Levandoski L, et al. Skin and adhesive issues with continuous glucose monitors: a sticky situation. J Diabetes Sci Technol. 2014;8(4):745–51.PubMedPubMedCentral
32.
Berg AK, Olsen BS, Thyssen JP, Zachariae C, Simonsen AB, Pilgaard K, et al. High frequencies of dermatological complications in children using insulin pumps or sensors. Pediatr Diabetes. 2018;19(4):733–40.PubMed
33.
Binder E, Lange O, Edlinger M, Meraner D, Abt D, Moser C, et al. Frequency of dermatological side effects of continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. 2015;123(4):260–4.
34.
Cope JU, Samuels-Reid JH, Morrison AE. Pediatric use of insulin pump technology: a retrospective study of adverse events in children ages 1-12 years. J Diabetes Sci Technol. 2012;6(5):1053–9.PubMedPubMedCentral
35.
Heinemann L, Krinelke L. Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion. J Diabetes Sci Technol. 2012;6(4):954–64.PubMedPubMedCentral
36.
Feig DS, Donovan LE, Corcoy R, Murphy KE, Amiel SA, Hunt KF, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017;390(10110):2347–59.PubMedPubMedCentral
37.
Polonsky WH, Hessler D, Ruedy KJ, Beck RW, Group DS. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care. 2017;40(6):736–41.PubMed
38.
Polonsky WH, Fisher L, Hessler D, Edelman SV. Investigating hypoglycemic confidence in type 1 and type 2 diabetes. Diabetes Technol Ther. 2017;19(2):131–6.PubMed
39.
Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care. 2003;26(4):1079–87.PubMed
40.
Nimri R, Weintrob N, Benzaquen H, Ofan R, Fayman G, Phillip M. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study. Pediatrics. 2006;117(6):2126–31.PubMed
41.
Patton SR, Clements MA. Psychological reactions associated with continuous glucose monitoring in youth. J Diabetes Sci Technol. 2016;10(3):656–61.PubMedPubMedCentral
42.
Mauras N, Beck R, Xing D, Ruedy K, Buckingham B, Tansey M, et al. A randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to <10 years. Diabetes Care. 2012;35(2):204–10.PubMedPubMedCentral
43.
Heller S, White D, Lee E, Lawton J, Pollard D, Waugh N, et al. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE trial. Health Technol Assess. 2017;21(20):1–278.PubMedPubMedCentral
44.
Rubin RR, Peyrot M, Group SS. Health-related quality of life and treatment satisfaction in the sensor-augmented pump therapy for A1C reduction 3 (STAR 3) trial. Diabetes Technol Ther. 2012;14(2):143–51.PubMedPubMedCentral
45.
Cemeroglu AP, Stone R, Kleis L, Racine MS, Postellon DC, Wood MA. Use of a real-time continuous glucose monitoring system in children and young adults on insulin pump therapy: patients’ and caregivers’ perception of benefit. Pediatr Diabetes. 2010;11(3):182–7.PubMed
46.
Hirsch IB, Abelseth J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther. 2008;10(5):377–83.PubMed
47.
Chase HP, Beck RW, Xing D, Tamborlane WV, Coffey J, Fox LA, et al. Continuous glucose monitoring in youth with type 1 diabetes: 12-month follow-up of the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Technol Ther. 2010;12(7):507–15.PubMed
48.
O'Connell MA, Donath S, Cameron FJ. Poor adherence to integral daily tasks limits the efficacy of CSII in youth. Pediatr Diabetes. 2011;12(6):556–9.PubMed
49.
Datye KA, Boyle CT, Simmons J, Moore DJ, Jaser SS, Sheanon N, et al. Timing of meal insulin and its relation to adherence to therapy in type 1 diabetes. J Diabetes Sci Technol. 2018;12(2):349–55.PubMed
50.
Tanenbaum ML, Adams RN, Hanes SJ, Barley RC, Miller KM, Mulvaney SA, et al. Optimal use of diabetes devices: clinician perspectives on barriers and adherence to device use. J Diabetes Sci Technol. 2017;11(3):484–92.PubMedPubMedCentral
51.
Driscoll KA, Johnson SB, Hogan J, Gill E, Wright N, Deeb LC. Insulin bolusing software: the potential to optimize health outcomes in type 1 diabetes mellitus. J Diabetes Sci Technol. 2013;7(3):646–52.PubMedPubMedCentral
52.
Patton SR, Driscoll KA, Clements MA. Adherence to insulin pump behaviors in young children with type 1 diabetes mellitus. J Diabetes Sci Technol. 2017;11(1):87–91.PubMed
53.
Driscoll KA, Wang Y, Bennett Johnson S, Lynch R, Stephens H, Willbur K, et al. White coat adherence in pediatric patients with type 1 diabetes who use insulin pumps. J Diabetes Sci Technol. 2016;10(3):724–9.PubMedPubMedCentral
54.
Driscoll KA, Johnson SB, Wang Y, Tang Y, Gill EC, Mitchell A, et al. Importance of manually entering blood glucose readings when wireless-compatible meters are not being used with an insulin pump. J Diabetes Sci Technol. 2013;7(4):898–903.PubMedPubMedCentral
55.
Driscoll KA, Johnson SB, Tang Y, Yang F, Deeb LC, Silverstein JH. Does blood glucose monitoring increase prior to clinic visits in children with type 1 diabetes? Diabetes Care. 2011;34(10):2170–3.PubMedPubMedCentral
56.
Driscoll KA, Johnson SB, Wang Y, Wright N, Deeb LC. Blood glucose monitoring before and after type 1 diabetes clinic visits. J Pediatr Psychol (in press). 2017.
57.
Barnard KD, Lloyd CE, Skinner TC. Systematic literature review: quality of life associated with insulin pump use in type 1 diabetes. Diabet Med. 2007;24(6):607–17.PubMed
58.
Hirose M, Beverly EA, Weinger K. Quality of life and technology: impact on children and families with diabetes. Current diabetes reports. 2012;12(6):711–20.PubMedPubMedCentral
59.
Hommel E, Olsen B, Battelino T, Conget I, Schütz-Fuhrmann I, Hoogma R, et al. Impact of continuous glucose monitoring on quality of life, treatment satisfaction, and use of medical care resources: analyses from the SWITCH study. Acta Diabetol. 2014;51(5):845–51.PubMedPubMedCentral
60.
Beck RW, Lawrence JM, Laffel L, Wysocki T, Xing D, Huang ES, et al. Quality-of-life measures in children and adults with type 1 diabetes: Juvenile Diabetes Research Foundation Continuous Glucose Monitoring randomized trial. Diabetes Care. 2010;33(10):2175–7.PubMed
61.
Markowitz JT, Pratt K, Aggarwal J, Volkening LK, Laffel LM. Psychosocial correlates of continuous glucose monitoring use in youth and adults with type 1 diabetes and parents of youth. Diabetes Technol Ther. 2012;14(6):523–6.PubMedPubMedCentral
62.
Rubin RR, Peyrot M. Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pump. J Diabetes Sci Technol. 2009;3(6):1402–10.PubMedPubMedCentral
63.
Hilliard ME, Goeke-Morey M, Cogen FR, Henderson C, Streisand R. Predictors of diabetes-related quality of life after transitioning to the insulin pump. J Pediatr Psychol. 2009;34(2):137–46.PubMed
64.
Nuboer R, Borsboom GJ, Zoethout JA, Koot HM, Bruining J. Effects of insulin pump vs. injection treatment on quality of life and impact of disease in children with type 1 diabetes mellitus in a randomized, prospective comparison. Pediatr Diabetes. 2008;9(4 Pt 1):291–6.PubMed
65.
Lind M, Polonsky W, Hirsch IB, Heise T, Bolinder J, Dahlqvist S, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA. 2017;317(4):379–87.PubMed
66.
Wong JC, Dolan LM, Yang TT, Hood KK. Insulin pump use and glycemic control in adolescents with type 1 diabetes: predictors of change in method of insulin delivery across two years. Pediatr Diabetes. 2015;16(8):592–9.PubMed
67.
Fisher L, Hessler D, Polonsky WH, Masharani U, Guzman S, Bowyer V, et al. T1-REDEEM: a randomized controlled trial to reduce diabetes distress among adults with type 1 diabetes. Diabetes Care. 2018;41:1862–9.PubMed
68.
Giani E, Snelgrove R, Volkening LK, Laffel LM. Continuous glucose monitoring (CGM) adherence in youth with type 1 diabetes: associations with biomedical and psychosocial variables. J Diabetes Sci Technol. 2017;11(3):476–83.PubMedPubMedCentral
69.
Rashotte J, Tousignant K, Richardson C, Fothergill-Bourbonnais F, Nakhla MM, Olivier P, et al. Living with sensor-augmented pump therapy in type 1 diabetes: adolescents’ and parents’ search for harmony. Can J Diabetes. 2014;38(4):256–62.PubMed
70.
Ritholz MD, Atakov-Castillo A, Beste M, Beverly EA, Leighton A, Weinger K, et al. Psychosocial factors associated with use of continuous glucose monitoring. Diabet Med. 2010;27(9):1060–5.PubMed
71.
Garmo A, Hornsten A, Leksell J. The pump was a saviour for me.’ Patients’ experiences of insulin pump therapy. Diabet Med. 2013;30(6):717–23.PubMed
72.
Seereiner S, Neeser K, Weber C, Schreiber K, Habacher W, Rakovac I, et al. Attitudes towards insulin pump therapy among adolescents and young people. Diabetes Technol Ther. 2010;12(1):89–94.PubMed
73.
James S, Perry L, Gallagher R, Lowe J. Diabetes educators: perceived experiences, supports and barriers to use of common diabetes-related technologies. J Diabetes Sci Technol. 2016;10(5):1115–21.PubMedPubMedCentral
74.
Hirsch IB. Clinical review: realistic expectations and practical use of continuous glucose monitoring for the endocrinologist. J Clin Endocrinol Metab. 2009;94(7):2232–8.PubMed
75.
Pickup JC, Ford Holloway M, Samsi K. Real-time continuous glucose monitoring in type 1 diabetes: a qualitative framework analysis of patient narratives. Diabetes Care. 2015;38(4):544–50.PubMed
76.
Wong JC, Boyle C, DiMeglio LA, Mastrandrea LD, Abel KL, Cengiz E, et al. Evaluation of pump discontinuation and associated factors in the T1D exchange clinic registry. J Diabetes Sci Technol. 2017;11(2):224–32.PubMedPubMedCentral
77.
Wysocki T, Hirschfeld F, Miller L, Izenberg N, Dowshen SA, Taylor A, et al. Consideration of insulin pumps or continuous glucose monitors by adolescents with type 1 diabetes and their parents: stakeholder engagement in the design of web-based decision aids. The Diabetes educator. 2016;42(4):395–407.PubMed
78.
Shivers JP, Mackowiak L, Anhalt H, Zisser H. “Turn it off!”: diabetes device alarm fatigue considerations for the present and the future. J Diabetes Sci Technol. 2013;7(3):789–94.PubMedPubMedCentral
79.
Messer LH, Johnson R, Driscoll KA, Jones J. Best friend or spy: a qualitative meta-synthesis on the impact of continuous glucose monitoring on life with type 1 diabetes. Diabet Med. 2018;35(4):409–18.PubMed
80.
Kropff J, DeJong J, Del Favero S, Place J, Messori M, Coestier B, et al. Psychological outcomes of evening and night closed-loop insulin delivery under free living conditions in people with type 1 diabetes: a 2-month randomized crossover trial. Diabet Med. 2017;34(2):262–71.PubMed
81.
Kerr D, Wizemann E, Senstius J, Zacho M, Ampudia-Blasco FJ. Stability and performance of rapid-acting insulin analogs used for continuous subcutaneous insulin infusion: a systematic review. J Diabetes Sci Technol. 2013;7(6):1595–606.PubMedPubMedCentral
82.
Wheeler BJ, Donaghue KC, Heels K, Ambler GR. Family perceptions of insulin pump adverse events in children and adolescents. Diabetes Technol Ther. 2014;16(4):204–7.PubMed
83.
Wheeler BJ, Heels K, Donaghue KC, Reith DM, Ambler GR. Insulin pump-associated adverse events in children and adolescents—a prospective study. Diabetes Technol Ther. 2014;16(9):558–62.PubMed
84.
Ross PL, Milburn J, Reith DM, Wiltshire E, Wheeler BJ. Clinical review: insulin pump-associated adverse events in adults and children. Acta Diabetol. 2015;52(6):1017–24.PubMed
85.
Kovatchev B, Anderson S, Heinemann L, Clarke W. Comparison of the numerical and clinical accuracy of four continuous glucose monitors. Diabetes Care. 2008;31(6):1160–4.PubMedPubMedCentral
86.
Christiansen M, Bailey T, Watkins E, Liljenquist D, Price D, Nakamura K, et al. A new-generation continuous glucose monitoring system: improved accuracy and reliability compared with a previous-generation system. Diabetes Technol Ther. 2013;15(10):881–8.PubMedPubMedCentral
87.
Laffel L. Improved accuracy of continuous glucose monitoring systems in pediatric patients with diabetes mellitus: results from two studies. Diabetes Technol Ther. 2016;18(Suppl 2):S223–33.PubMed
88.
Faccioli S, Del Favero S, Visentin R, Bonfanti R, Iafusco D, Rabbone I, et al. Accuracy of a CGM sensor in pediatric subjects with type 1 diabetes. Comparison of three insertion sites: arm, abdomen, and gluteus. J Diabetes Sci Technol. 2017;11(6):1147–54.PubMedPubMedCentral
89.
Vloemans AF, van Beers CAJ, de Wit M, Cleijne W, Rondags SM, Geelhoed-Duijvestijn PH, et al. Keeping safe. Continuous glucose monitoring (CGM) in persons with type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. Diabet Med. 2017;34(10):1470–6.PubMed
90.
Ruiz JL, Sherr JL, Cengiz E, Carria L, Roy A, Voskanyan G, et al. Effect of insulin feedback on closed-loop glucose control: a crossover study. J Diabetes Sci Technol. 2012;6(5):1123–30.PubMedPubMedCentral
91.
Doyle FJ 3rd, Huyett LM, Lee JB, Zisser HC, Dassau E. Closed-loop artificial pancreas systems: engineering the algorithms. Diabetes Care. 2014;37(5):1191–7.PubMedPubMedCentral
92.
Steil GM. Algorithms for a closed-loop artificial pancreas: the case for proportional-integral-derivative control. J Diabetes Sci Technol. 2013;7(6):1621–31.PubMedPubMedCentral
93.
Bequette BW. Algorithms for a closed-loop artificial pancreas: the case for model predictive control. J Diabetes Sci Technol. 2013;7(6):1632–43.PubMedPubMedCentral
94.
Forlenza GP, Cameron FM, Ly TT, Lam D, Howsmon DP, Baysal N, et al. Fully closed-loop multiple model probabilistic predictive controller artificial pancreas performance in adolescents and adults in a supervised hotel setting. Diabetes Technol Ther. 2018;20(5):335–43.PubMed
95.
Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(7):501–12.PubMed
96.••
Bekiari E, Kitsios K, Thabit H, Tauschmann M, Athanasiadou E, Karagiannis T, et al. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ (Clinical research ed). 2018;361:k1310 Review of 40 studies using the artificial pancreas showing their clinical benefit of increasing time in range both in real-world settings and well-controlled research settings.
97.
Bergenstal RM, Garg S, Weinzimer SA, Buckingham BA, Bode BW, Tamborlane WV, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316(13):1407–8.PubMed
98.
Messer LH, Forlenza GP, Sherr JL, Wadwa RP, Buckingham BA, Weinzimer SA, et al. Optimizing hybrid closed-loop therapy in adolescents and emerging adults using the MiniMed 670G system. Diabetes Care. 2018;41(4):789–96.PubMed
99.
Berget C, Messer LH, Pyle L, Westfall E, Forlenza GP, Driscoll KA. Real-world use of hybrid closed-loop therapy in pediatric patients with type 1 diabetes. Diabetes. 2018;67(S1):A254.
100.
Barnard KD, Venkat MV, Close K, Heinemann L, Weissberg-Benchell J, Hood KK, et al. PsychDT working group: report psychosocial aspects of artificial pancreas systems. J Diabetes Sci Technol. 2015;9(4):925–8.PubMedPubMedCentral
101.
Iturralde E, Tanenbaum ML, Hanes SJ, Suttiratana SC, Ambrosino JM, Ly TT, et al. Expectations and attitudes of individuals with type 1 diabetes after using a hybrid closed loop system. The Diabetes educator. 2017;43(2):223–32.PubMed
102.
Farrington C. Hacking diabetes: DIY artificial pancreas systems. Lancet Diabetes Endocrinol. 2017;5(5):332.PubMed
103.
Weissberg-Benchell J, Hood K, Laffel L, Heinemann L, Ball D, Kowalski A, et al. Toward development of psychosocial measures for automated insulin delivery. J Diabetes Sci Technol. 2016;10(3):799–801.PubMed
Metadata
Title
Biopsychosocial Factors Associated With Satisfaction and Sustained Use of Artificial Pancreas Technology and Its Components: a Call to the Technology Field
Authors
Gregory P. Forlenza
Laurel H. Messer
Cari Berget
R. Paul Wadwa
Kimberly A. Driscoll
Publication date
01-11-2018
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 11/2018
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-018-1078-1

Other articles of this Issue 11/2018

Current Diabetes Reports 11/2018 Go to the issue

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (B Conway and H Keenan, Section Editors)

Red Meat Consumption (Heme Iron Intake) and Risk for Diabetes and Comorbidities?

Diabetes Epidemiology (E Selvin and K Foti, Section Editors)

Advancing Measurement of Diabetes at the Population Level

Diabetes and Pregnancy (M-F Hivert and CE Powe, Section Editors)

Oral Agents for the Treatment of Gestational Diabetes

Health Care Delivery Systems and Implementation in Diabetes (ME McDonnell and AR Sadhu, Section Editors)

Building Toward a Population-Based Approach to Diabetes Screening and Prevention for US Adults

Psychosocial Aspects (SS Jaser, Section Editor)

Diabetes, Depression, and Cognition: a Recursive Cycle of Cognitive Dysfunction and Glycemic Dysregulation

Health Care Delivery Systems and Implementation in Diabetes (ME McDonnell and AR Sadhu, Section Editors)

App-Based Insulin Calculators: Current and Future State
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits